Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 9, 2004, Pages 1515-1520

  Rylander Rudqvist, Tove ^a   Wedrén, Sara ^a   Jonasdottir, Gudrun ^a   Ahlberg, Susanne ^a   Weiderpass, Elisabete ^a,b,c,d   Persson, Ingemar ^a,e   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c FINNISH CANCER REGISTRY   (Finland)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ALGORITHM; ALLELE; ARTICLE; BODY MASS; CALCULATION; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FEMALE; GENOTOXICITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; HYDROXYLATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POPULATION; POSTMENOPAUSE; PRIORITY JOURNAL; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SWEDEN;

AGED; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RISK; STATISTICS; SWEDEN;

EID: 4444323259     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003;9:27-31.
2. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001; 943:296-315.
3. Terry PD, Rohan TE, Franceschi S, Weiderpass E. Cigarette smoking and the risk of endometrial cancer. Lancet Oncol 2002;3:470-80.
4. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.
5. Moradi T, Weiderpass E, Signorello LB, Persson I, Nyren O, Adami HO. Physical activity and postmenopausal endometrial cancer risk (Sweden). Cancer Causes Control 2000;11:829-37.
6. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-19.
7. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids 1981;37:195-203.
8. Hakkola J, Pasanen M, Pelkonen O, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 1997;18:391-7.
9. Bofinger DP, Feng L, Chi LH, et al. Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium. Toxicol Sci 2001;62:299-314.
10. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24: 353-6.
11. Li JJ, Li SA. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987;46:1858-63.
12. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 β-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81.
13. Stoilov I, Akarsu AN, Alozie I, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62: 573-84.
14. Rylander-Rudqvist T, Wedren S, Granath F, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003;24:1533-9.
15. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-13.
16. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM. Specificity of 17-estradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica 2001;31:163-76.
17. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33.
18. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-94.
19. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P 450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4.
20. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
21. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:489-92.
22. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol 2002;76:643-9.
23. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res 2003;63:3913-8.
24. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
25. Weiderpass E, Baron JA. Cigarette smoking, alcohol consumption, and endometrial cancer risk: a population-based study in Sweden. Cancer Causes Control 2001;12:239-47.
26. Weiderpass E, Baron JA, Adami HO, et al. Low-potency estrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353: 1824-8.
27. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000;11:185-92.
28. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994;145:1301-8.
29. Pastinen T, Partanen J, Syvanen AC. Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation. Clin Chem 1996;42:1391-7.
30. Prince JA, Feuk L, Howell WM, et al. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res 2001;11:152-62.
31. McLellan RA, Oscarson M, Hidestrand M, et al. Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 2000;378:175-81.
32. Howell WM, Jobs M, Gyllensten U, Brookes AJ. Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat Biotechnol 1999;17:87-8.
33. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc 1977;39:1-38.
34. Bao H, Vepakomma M, Sarkar MA. Benzo(a)pyrene exposure induces CYP1A1 activity and expression in human endometrial cells. J Steroid Biochem Mol Biol 2002;81:37-45.
35. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986; 315:1305-9.